Morningstar

uniQure to Announce Third Quarter 2026 Financial Results

Provided by GlobeNewswire

LEXINGTON, Mass. and AMSTERDAM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report third quarter 2026 financial results before market open on Wednesday, November 4, 2026. Management will then host a conference call at 8:30 a.m. ET.

The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID 5075555. If you are joining the conference call, please join 15 minutes before the start time.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com

uniQure Contacts:

FOR INVESTORS:     
FOR MEDIA:
  
Chiara RussoTom Malone
Direct: 781-491-4371Direct: 339-970-7558
Mobile: 617-306-9137Mobile:339-223-8541
c.russo@uniQure.comt.malone@uniQure.com



The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

4 Growth Stocks to Buy While They’re Still Undervalued

Plus, the outlook for the AI trade after last week’s selloff.
David Sekera, CFA and Sarah Hansen

3 of the Best Core Stocks to Own

These core stocks with wide economic moats are good long-term investments if you can buy them at a discount.
Susan Dziubinski

3 Great New ETFs From 2026

These ETFs stand out from the rest.
Brendan McCann, CFA

Retirees: 5 Reasons to Consider Index Funds and ETFs

Low fees are just the start. These funds can also make it easier to draw cash for living expenses and manage your portfolio.
Christine Benz

This Newly Undervalued Stock Has Plenty of Growth Ahead

After the recent selloff, this 4-star stock looks more attractive as demand grows for the materials used to make advanced chips.
Seth Goldstein, CFA

Sponsor Center

Site Index
United States Flag United States

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.